FDA 483 - Kamran Qureshi, M.D. - April 28, 2023

An FDA inspection of Kamran Qureshi, M.D. in Saint Louis, MO, identified a significant issue regarding the conduct of an investigation. The clinical investigator failed to maintain control and accountability for study drugs, specifically eleven missing study kits. This indicates a serious lapse in adherence to the investigational plan and regulatory requirements for drug management.